| Autor: |
Kangussu, Lucas, Campagnole-Santos, Maria Jose, Souza Santos, Robson Augusto, Kappes Becker, Lenice, Sinisterra Millán, Ruben Dario, Motta-Santos, Daisy, Totou, Nádia, Moura, Samara, Coelho, Daniel |
| Předmět: |
|
| Zdroj: |
International Journal of Sports Medicine; 2018, Vol. 39 Issue 10, p743-748, 6p |
| Abstrakt: |
The development of new strategies to attenuate exercise-induced muscle damage may be helpful for training regimens. The aim of this study was to determine whether a oral formulation of angiotensin Ang-(1-7)[HPβCD/Ang-(1-7)] is effective to reduce pain, and muscle damage markers after eccentric-overload exercise. HPβCD (Placebo) and HPβCD/Ang-(1-7) (Ang-(1-7) group were treated for 7 days (one capsule/day). The pain was measured by visual analogue scale, maximal strength (MS) using force platform. Blood samples were collected for cytokines and creatine kinase (CK) analysis. The Ang-(1-7)-treated group reported less pain immediately (3.46 ± 0.64 vs. placebo 3.80 ± 0.77 cm) and 24 h after exercise (3.07 ± 0.71 vs. 3.73 ± 0.58 cm placebo) and higher MS at 24 h (24 ± 12 N) and 48 h (30 ± 15 N) vs. placebo (-8 ± 9 N and -10 ± 9 N). The CK for Ang-(1-7) (0.5 ± 0.1 and 0.9 ± 0.2 U/L) were lower at 48 and 72 h vs. placebo (fold changes of 1.7 ± 0.5 and 1.5 ± 0.3 U/L). The TNF-α level was lower in the treated group post-exercise (38 ± 2.5 pg/ml) vs. placebo (45 ± 2.9 pg/ml) but no significant changes were observed for IL-6 and IL-10. Our data indicate that treatment with Ang-(1-7) may attenuate pain, some of the muscle damage markers and improves performance following eccentric exercise. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
